CX3CR1 and long COVID-19: Hence, we targeted CCR5 and fractalkine receptors using maraviroc and pravastatin, respectively, hypothesizing that this combination could be therapeutically effective in treating vascular endothelialitis and resolving symptoms associated with PASC.